Feiyue Zhang1, Bide Duan1, Yanming Liu2, Cuicui Wang1. 1. Obstetrics Department, Zibo Central Hospital Zibo 255000, Shandong, China. 2. Rehabilitation Medicine Department, Zibo Central Hospital Zibo 255000, Shandong, China.
Abstract
OBJECTIVE: To determine the clinical efficacy of aspirin combined with labetalol on gestational hypertension (GH) and its influence on serum pregnancy associated plasma protein-A (PAPP-A), adiponectin (APN), and high mobility group box-1 (HMGB1). METHODS: A total of 146 patients with GH admitted to the Zibo Central Hospital between April 2018 and January 2020 were analyzed retrospectively. The control group (Con group, n=71) was treated by labetalol monotherapy, and on this basis, the research group (Res group, n=75) was additionally given aspirin. The following criteria of the 2 groups were evaluated: total effectiveness rate, incidence of adverse reactions, blood pressure-associated indices, coagulation function-associated indices, changes in serum PAPP-A, APN, and HMGB1 levels, adverse maternal and infant outcomes, and neonatal Apgar score. RESULTS: After therapy, the Res group showed a notably higher total effective rate than the Con group, with no remarkable difference in the incidence of adverse reactions. Additionally, compared to the Con group, the Res group showed notably lower systolic blood pressure (SBP) and diastolic blood pressure (DBP), greatly improved coagulation function, significantly lower levels of serum PAPP-A and HMGB1, and significantly higher level of serum APN. Moreover, the incidence of adverse maternal and infant outcomes in the Res group was much lower than that in the Con group after therapy, and the one- and five-min Apgar scores of neonates in the Res group were both notably higher than those in the Con group after delivery. CONCLUSION: For patients with GH, aspirin combined with labetalol can effectively control blood pressure, improve coagulation function and clinical efficacy, lower serum PAPP-A and HMGB1, and increase serum APN, and ameliorate maternal and infant outcome. AJTR
OBJECTIVE: To determine the clinical efficacy of aspirin combined with labetalol on gestational hypertension (GH) and its influence on serum pregnancy associated plasma protein-A (PAPP-A), adiponectin (APN), and high mobility group box-1 (HMGB1). METHODS: A total of 146 patients with GH admitted to the Zibo Central Hospital between April 2018 and January 2020 were analyzed retrospectively. The control group (Con group, n=71) was treated by labetalol monotherapy, and on this basis, the research group (Res group, n=75) was additionally given aspirin. The following criteria of the 2 groups were evaluated: total effectiveness rate, incidence of adverse reactions, blood pressure-associated indices, coagulation function-associated indices, changes in serum PAPP-A, APN, and HMGB1 levels, adverse maternal and infant outcomes, and neonatal Apgar score. RESULTS: After therapy, the Res group showed a notably higher total effective rate than the Con group, with no remarkable difference in the incidence of adverse reactions. Additionally, compared to the Con group, the Res group showed notably lower systolic blood pressure (SBP) and diastolic blood pressure (DBP), greatly improved coagulation function, significantly lower levels of serum PAPP-A and HMGB1, and significantly higher level of serum APN. Moreover, the incidence of adverse maternal and infant outcomes in the Res group was much lower than that in the Con group after therapy, and the one- and five-min Apgar scores of neonates in the Res group were both notably higher than those in the Con group after delivery. CONCLUSION: For patients with GH, aspirin combined with labetalol can effectively control blood pressure, improve coagulation function and clinical efficacy, lower serum PAPP-A and HMGB1, and increase serum APN, and ameliorate maternal and infant outcome. AJTR
Authors: Michele K Saums; Caroline C King; Jenna C Adams; Anandi N Sheth; Martina L Badell; Marisa Young; Lynn M Yee; Ellen G Chadwick; Denise J Jamieson; Lisa B Haddad Journal: Obstet Gynecol Date: 2019-12 Impact factor: 7.661